Cited by 176RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryBarrier Structure and Function Studies

The DOI matches its Crossref record; 55 of the 59 references it cites were found in a registry or an index.

shRNA and siRNA delivery to the brain

Open access

Pardridge, William M.·2007·Advanced Drug Delivery Reviews

DOI 10.1016/j.addr.2007.03.008PMC PMC3572210

Open this paper in CoChat — free account

Abstract

The limiting factor in in vivo RNA interference (RNAi) is delivery. Drug delivery methods that are effective in cell culture may not be practical in vivo for intravenous RNAi applications. Nucleic acid drugs are highly charged and do not cross cell membranes by free diffusion. Therefore, the in vivo delivery of RNAi therapeutics must use targeting technology that enables the RNAi therapeutic to traverse biological membrane barriers in vivo. For RNAi of the brain, the nucleic acid-based drug must first cross the brain capillary endothelial wall, which forms the blood-brain barrier (BBB) in vivo, and then traverses the brain cell plasma membrane. Similar to the delivery of non-viral gene therapies, plasmid DNA encoding for short hairpin RNA (shRNA) may be delivered to the brain following intravenous administration with pegylated immunoliposomes (PILs). The plasmid DNA is encapsulated in a 100 nm liposome, which is pegylated, and conjugated with receptor specific targeting monoclonal antibodies (MAb). Weekly, intravenous RNAi with PILs enables a 90% knockdown of the human epidermal growth factor receptor, which results in a 90% increase in survival time in mice with intra-cranial brain cancer. Similar to the delivery of antisense agents, short interfering RNAi (siRNA) duplexes can be delivered with the combined use of targeting MAb's and avidin-biotin technology. The siRNA is mono-biotinylated in parallel with the production of a conjugate of the targeting MAb and streptavidin. Intravenous RNAi requires the combined use of RNAi technology and a drug targeting technology that is effective in vivo.

Integrity signals

Registry

Crossref · 10.1016/j.addr.2007.03.008

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
EGFR and cancer prognosis.
Nicholson, R., Gee, J., & Harper, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,132
Avidin
Green, N. M. (1975) · Advances in protein chemistry · doi:10.1016/s0065-3233(08)60411-8 · Cited by 1,472
Gene silencing in mammals by small interfering RNAs
McManus, M. T., & Sharp, P. A. (2002) · Nature Reviews Genetics · doi:10.1038/nrg908 · Cited by 1,400
Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?
Stein, C., & Cheng, Y. C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,300
RNAi in Human Cells
Chiu, Y., & Rana, T. M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00652-4 · Cited by 400
Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo.
Pardridge, W. M., Buciak, J. L., & Friden, P. M. (1991) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20567-5 · Cited by 358
Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain Cancer
Zhang, Y., Zhang, Y., Bryant, J., Charles, A. C., Boado, R. J., & Pardridge, W. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0740 · Cited by 330
EGF mutant receptor vIII as a molecular target in cancer therapy.
Kuan, C., Wikstrand, C. J., & Bigner, D. D. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080083 · Cited by 325
Human Insulin Receptor Monoclonal Antibody Undergoes High Affinity Binding to Human Brain Capillaries in Vitro and Rapid Transcytosis Through the Blood–Brain Barrier in Vivo in the Primate
Pardridge, W. M., Kang, Y., Buciak, J. L., & Yang, J. (1995) · Pharmaceutical Research · doi:10.1023/a:1016244500596 · Cited by 324
Targeting Rat Anti-Mouse Transferrin Receptor Monoclonal Antibodies through Blood-Brain Barrier in Mouse
Lee, H., Engelhardt, B., Lesley, J., Bickel, U., & Pardridge, W. M. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35388-1 · Cited by 287
Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements in Vivo
Wu, C. H., Wilson, J. M., & Wu, G. Y. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)71447-6 · Cited by 286
Stabilization of poly-l-lysine/DNA polyplexes for in vivo gene delivery to the liver
Kwoh, D. Y., Coffin, C. C., Lollo, C. P., Jovenal, J., Banaszczyk, M., Mullen, P. M., Phillips, A. T., Amini, A., Fabrycki, J., Bartholomew, R. M., et al. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00274-7 · Cited by 276
Brain-specific expression of an exogenous gene after i.v. administration
Shi, N., Zhang, Y., Zhu, C., Boado, R. J., & Pardridge, W. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221450098 · Cited by 273
Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.
Cossum, P. A., Sasmor, H. M., Dellinger, D., Truong, L., Cummins, L. M., Owens, S. R., Markham, P. M., Shea, J. P., & Crooke, S. T. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39459-0 · Cited by 265
Noninvasive gene targeting to the brain
Shi, N., & Pardridge, W. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130187497 · Cited by 253
Neuroprotection with noninvasive neurotrophin delivery to the brain
Wu, D., & Pardridge, W. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.254 · Cited by 209
Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor
Coloma, M. J., Lee, H., Kurihara, A., Landaw, E. M., Boado, R. J., Morrison, S. L., & Pardridge, W. M. (2000) · Pharmaceutical Research · doi:10.1023/a:1007592720793 · Cited by 207
Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism.
Zhang, Y., Calon, F., Zhu, C., Boado, R. J., & Pardridge, W. M. (2003) · Human Gene Therapy · doi:10.1089/10430340360464660 · Cited by 194
Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo.
Pardridge, W. M., Boado, R. J., & Kang, Y. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5592 · Cited by 193
Global non-viral gene transfer to the primate brain following intravenous administration
Zhang, Y., Schlachetzki, F., & Pardridge, W. M. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00018-7 · Cited by 179
Neuroprotection in Transient Focal Brain Ischemia After Delayed Intravenous Administration of Brain-Derived Neurotrophic Factor Conjugated to a Blood-Brain Barrier Drug Targeting System
Zhang, Y., & Pardridge, W. M. (2001) · Stroke · doi:10.1161/01.str.32.6.1378 · Cited by 175
Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages
Marcus-Sekura, C. J., Woerner, A. M., Shinozuka, K., Zon, G., & Quinnan, G. V. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.14.5749 · Cited by 175
Conjugation of brain-derived neurotrophic factor to a blood–brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin
Zhang, Y., & Pardridge, W. M. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03108-5 · Cited by 167
Rapid transferrin efflux from brain to blood across the blood–brain barrier
Zhang, Y., & Pardridge, W. M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00222.x · Cited by 159
Receptor-Mediated Gene Targeting to Tissues In Vivo Following Intravenous Administration of Pegylated Immunoliposomes
Shi, N., Boado, R. J., & Pardridge, W. M. (2001) · Pharmaceutical Research · doi:10.1023/a:1010910523202 · Cited by 157
Brain Drug Targeting: The Future of Brain Drug Development
Pardridge, W. M. (2001) · Cited by 150
Antisense Gene Therapy of Brain Cancer with an Artificial Virus Gene Delivery System
Zhang, Y., Zhu, C., & Pardridge, W. M. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0633 · Cited by 144
Normalization of Striatal Tyrosine Hydroxylase and Reversal of Motor Impairment in Experimental Parkinsonism with Intravenous Nonviral Gene Therapy and a Brain-Specific Promoter
Zhang, Y., Schlachetzki, F., Zhang, Y.-F., Boado, R. J., & Pardridge, W. M. (2004) · Human Gene Therapy · doi:10.1089/104303404322959498 · Cited by 134
Receptor‐mediated delivery of an antisense gene to human brain cancer cells
Zhang, Y., Lee, H. J., Boado, R. J., & Pardridge, W. M. (2002) · The Journal of Gene Medicine · doi:10.1002/jgm.255 · Cited by 132
Enhanced Neuroprotective Effects of Basic Fibroblast Growth Factor in Regional Brain Ischemia after Conjugation to a Blood-Brain Barrier Delivery Vector
Song, B.-W., Vinters, H. V., Wu, D., & Pardridge, W. M. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.605 · Cited by 125
In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats
Zhang, Y., Boado, R. J., & Pardridge, W. M. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.449 · Cited by 113
Delivery of β-Galactosidase to Mouse Brain via the Blood-Brain Barrier Transferrin Receptor
Zhang, Y., & Pardridge, W. M. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.082974 · Cited by 110
Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups
Tidd, D., & Warenius, H. M. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.283 · Cited by 108
An Antibody-Avidin Fusion Protein Specific for the Transferrin Receptor Serves as a Delivery Vehicle for Effective Brain Targeting: Initial Applications in Anti-HIV Antisense Drug Delivery to the Brain
Penichet, M. L., Kang, Y., Pardridge, W. M., Morrison, S. L., & Shin, S.-U. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4421 · Cited by 100
Contribution of Plasmid DNA to Hepatotoxicity after Systemic Administration of Lipoplexes
Loisel, S., Gall, C., Doucet, L., Férec, C., & Floch, V. (2001) · Human Gene Therapy · doi:10.1089/104303401300057405 · Cited by 98
Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer.
Zhang, Y., Schlachetzki, F., Li, J. Y., Boado, R. J., & Pardridge, W. M. (2003) · PubMed · Cited by 95
Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system.
Wu, D., & Pardridge, W. M. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20939-9 · Cited by 76
The effects of polycations on vascular permeability in the rat. A proposed role for charge sites.
Vehaskari, V. M., Chang, C. T., Stevens, J., & Robson, A. M. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111290 · Cited by 76
Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology.
Suzuki, T., Wu, D., Schlachetzki, F., Li, J. Y., Boado, R. J., & Pardridge, W. M. (2004) · PubMed · Cited by 62
Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier.
Kurihara, A., & Pardridge, W. M. (1999) · PubMed · Cited by 61
PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli.
Abé, T., Terada, K., Wakimoto, H., Inoüe, R., Tyminski, E., Bookstein, R., Basilion, J. P., & Chiocca, E. A. (2003) · PubMed · Cited by 59
Insulin Receptors in Human Ocular Tissues
Naeser, P. (1997) · Upsala Journal of Medical Sciences · doi:10.3109/03009739709178930 · Cited by 57
CAPILLARY PERMEABILITY
(1927) · JAMA · doi:10.1001/jama.1927.02690210050017 · Cited by 54
Gene Targeting In Vivo with Pegylated Immunoliposomes
Pardridge, W. M. (2003) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(03)73032-8 · Cited by 53
Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu, D., Boado, R. J., & Pardridge, W. M. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12250-7 · Cited by 51
Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation
Norman, J., Denham, W., Denham, D. W., Yang, J. W., Carter, G., Abouhamze, A. S., Tannahill, C., MacKay, S. L., & Moldawer, L. L. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301240 · Cited by 47
Widespread expression of an exogenous gene in the eye after intravenous administration.
Zhu, C., Zhang, Y., & Pardridge, W. M. (2002) · PubMed · Cited by 44
Non–Sequence-Specific Inhibition of Transferrin Receptor Expression in HL-60 Leukemia Cells by Phosphorothioate Oligodeoxynucleotides
Ho, P. T., Ishiguro, K., Wickstrom, E., & Sartorelli, A. C. (1991) · Antisense Research and Development · doi:10.1089/ard.1991.1.329 · Cited by 42
Electron microscopic visualization of insulin translocation into the cytoplasm and nuclei of intact H35 hepatoma cells using covalently linked Nanogold-insulin
Shah, N., Zhang, S., Harada, S., Smith, R. M., & Jarett, L. (1995) · Endocrinology · doi:10.1210/endo.136.7.7789307 · Cited by 35
Free cationic liposomes inhibit the inflammatory response to cationic lipid–DNA complex injected intravenously and enhance its transfection efficiency
Elouahabi, A., Flamand, V., Özkan, S. A., Paulart, F., Vandenbranden, M., Goldman, M., & Ruysschaert, J. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00032-1 · Cited by 30
Organ‐specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice
Zhu, C., Zhang, Y., Zhang, Y., Li, J. Y., Boado, R. J., & Pardridge, W. M. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.575 · Cited by 29
Decline in Exogenous Gene Expression in Primate Brain Following Intravenous Administration Is Due to Plasmid Degradation
Chu, C., Zhang, Y., Boado, R. J., & Pardridge, W. M. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0274-x · Cited by 28
Brain Drug Targeting: The Future of Brain Drug Development
Dufresne, R. L. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a290 · Cited by 18
In vitro stability of α-Helical peptide nucleic acids (αPNAs)
Garner, P., Sherry, B. D., Moilanen, S. B., & Huang, Y. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00422-x · Cited by 12

Sorted by citations

Activatable Photosensitizers for Imaging and Therapy
Lovell, J. F., Liu, T. W. B., Chen, J., & Zheng, G. (2010) · Chemical Reviews · doi:10.1021/cr900236h · Cited by 1,718
The promises and pitfalls of RNA-interference-based therapeutics
Castanotto, D., & Rossi, J. J. (2009) · Nature · doi:10.1038/nature07758 · Cited by 1,241
Delivery of siRNA Therapeutics: Barriers and Carriers
Wang, J., Lu, Z., Wientjes, M. G., & Au, J. L. ‐. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9210-4 · Cited by 820
Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
Gabathuler, R. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.028 · Cited by 829
Site-specific antibody drug conjugates for cancer therapy
Panowski, S. H., Bhakta, S., Raab, H. E., Polakis, P. G., & Junutula, J. R. (2013) · mAbs · doi:10.4161/mabs.27022 · Cited by 677

See all 176

Authors: Pardridge, W. M.
Affiliations: University of California, Los Angeles (US)
Corresponding author: Pardridge, William M.
ORCID: Pardridge, William M.
Venue: Advanced Drug Delivery Reviews
Publisher: Elsevier BV
Published: 2007-03
Volume: 59
Issue: 2-3
Pages: 141-152
ISSN: 0169-409X (ISSN-L)
DOI: 10.1016/j.addr.2007.03.008
PMC: PMC3572210
OpenAlex: W2031687291
Cited by: 176
References: 59
Citations by year: 2025: 4 · 2024: 6 · 2023: 9 · 2022: 6 · 2021: 8 · 2020: 6 · 2019: 10 · 2018: 4 · 2017: 10 · 2016: 6 · 2015: 8 · 2014: 3 · 2013: 18 · 2012: 12
FWCI: 1.23
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Advanced Drug Delivery Reviews (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Neurological Disorders and Stroke (R01NS053540)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords: RNA interference, shRNA delivery, siRNA delivery, brain, blood-brain barrier, monoclonal antibody targeting, intravenous administration, epidermal growth factor receptor, brain cancer, nucleic acid drug delivery, membrane crossing
MeSH terms: Animals, Brain, Carrier Proteins, Humans, Plasmids, Reproducibility of Results, Drug Delivery Systems, RNA, Small Interfering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

shRNA and siRNA delivery to the brain

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks